Andrew J. Ambrose

Andrew J. Ambrose

Auto-generated profile, based on publicly available information

Andrew J. Ambrose

College of Pharmacy, Department of Pharmacology and Toxicology, The University of Arizona, 1703 E. Mabel Street, P.O. Box 210207, Tucson, Arizona 85721, United States

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 May 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
AAAndrew J. Ambrose
Andrew J. Ambrose
ECEli Chapman
Eli Chapman

1 July 2016 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
SASanofar Abdeen
Sanofar Abdeen
NSNilshad Salim
Nilshad Salim
NMNajiba Mammadova
Najiba Mammadova
CSCorey M. Summers
Corey M. Summers
RFRochelle Frankson
Rochelle Frankson
SJSteven M. Johnson
Steven M. Johnson

30 July 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SASanofar Abdeen
Sanofar Abdeen
TKTrent Kunkle
Trent Kunkle
NSNilshad Salim
Nilshad Salim
RARay Anne-Marie
Ray Anne-Marie
NMNajiba Mammadova
Najiba Mammadova
SJSteven M. Johnson
Steven M. Johnson

1 June 2018 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
PDF file
MDMatthew Dodson
Matthew Dodson
PLPengfei Liu
Pengfei Liu
TJTao Jiang
Tao Jiang
AAAndrew J. Ambrose
Andrew J. Ambrose
GLGang Luo
Gang Luo
DZDonna D. Zhang
Donna D. Zhang
Environmental exposure to arsenic is linked to adverse health effects including cancer and diabetes. Pleiotropic cellular effects are observed with arsenic exposure. Previously, we demonstrated that arsenic dysregulated the autophagy pathway at low, environmentally relevant concentrations. Here, we show that arsenic blocks autophagy by preventing autophagosome-lysosome fusion. Specifically, arsenic disrupts formation of the STX17-SNAP29-VAMP8 SNARE complex, where SNAP29 mediates vesicle fusion through bridging STX17-containing autophagosomes to VAMP8-bearing lysosomes. Mechanistically, arsenic inhibits SNARE complex formation, at least in part, by enhancing O-GlcNAcylation of SNAP29. Transfection of O-GlcNAcylation defective, but not wild type, SNAP29 into CRISPR-mediated SNAP29 knockout cells abolishes arsenic-mediated autophagy inhibition. These findings reveal a mechanism by which low-levels of arsenic perturb proteostasis through inhibition of SNARE complex formation, providing a possible therapeutic target for disease intervention in the more than 200 million people exposed to unsafe levels of arsenic.

1 September 2018 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
TPTara L. Peters
Tara L. Peters
JTJoseph Tillotson
Joseph Tillotson
AYAlison M. Yeomans
Alison M. Yeomans
SWSarah Wilmore
Sarah Wilmore
ELElizabeth Lemm
Elizabeth Lemm
JSJonathan Schatz
Jonathan Schatz
Purpose: The DEAD-box RNA helicase eIF4A1 carries out the key enzymatic step of cap-dependent translation initiation and is a well-established target for cancer therapy, but no drug against it has entered evaluation in patients. We identified and characterized a natural compound with broad antitumor activities that emerged from the first target-based screen to identify novel eIF4A1 inhibitors. Experimental Design: We tested potency and specificity of the marine compound elatol versus eIF4A1 ATPase activity. We also assessed eIF4A1 helicase inhibition, binding between the compound and the target including binding site mutagenesis, and extensive mechanistic studies in cells. Finally, we determined maximum tolerated dosing in vivo and assessed activity against xenografted tumors. Results: We found elatol is a specific inhibitor of ATP hydrolysis by eIF4A1 in vitro with broad activity against multiple tumor types. The compound inhibits eIF4A1 helicase activity and binds the target with unexpected 2:1 stoichiometry at key sites in its helicase core. Sensitive tumor cells suffer acute loss of translationally regulated proteins, leading to growth arrest and apoptosis. In contrast to other eIF4A1 inhibitors, elatol induces markers of an integrated stress response, likely an off-target effect, but these effects do not mediate its cytotoxic activities. Elatol is less potent in vitro than the well-studied eIF4A1 inhibitor silvestrol but is tolerated in vivo at approximately 100× relative dosing, leading to significant activity against lymphoma xenografts. Conclusions: Elatol's identification as an eIF4A1 inhibitor with in vivo antitumor activities provides proof of principle for target-based screening against this highly promising target for cancer therapy. Clin Cancer Res; 24(17); 4256–70. ©2018 AACR.

1 September 2017 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
JTJoseph Tillotson
Joseph Tillotson
MKMagdalena Kedzior
Magdalena Kedzior
LGLarissa Guimarães
Larissa Guimarães
ARAlison B. Ross
Alison B. Ross
TPTara L. Peters
Tara L. Peters
ECEli Chapman
Eli Chapman